Roles of protein kinase B/Akt in lung cancer

Frontiers in Bioscience - Elite

Volumn 2 E, Issue 4, 2010, Pages 1472-1484

  Xu, Cheng Xiong ^a   Jin, Hua ^b   Shin, Ji Young ^c   Kim, Ji Eun ^c,d   Hong, Choong Man ^e   Cho, Myung Haing ^c,d  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^c Seoul National University   (South Korea)

^d Seoul National University   (South Korea)

^e National Institute of Food and Drug Safety Evaluation   (South Korea)

Author keywords

Akt; Lung tumorigenesis; Protein kinase B; Therapeutic resistance

Indexed keywords

PROTEIN KINASE B;

ENZYME ACTIVATION; ENZYMOLOGY; HUMAN; LUNG TUMOR; METABOLISM; REVIEW; SIGNAL TRANSDUCTION;

ENZYME ACTIVATION; HUMANS; LUNG NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 77957368257     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: None     Document Type: Article

References (141)

1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu and M. J. Thun: Cancer statistics, 2009. CA Cancer J Clin, 59(4), 225-49 (2009)
2. P. Nana-Sinkam, H. Golpon, R. L. Keith, R. J. Oyer, S. Sotto-Santiago, M. D. Moore, W. Franklin, R. A. Nemenoff and M. W. Geraci: Prostacyclin in human non-small cell lung cancers. Chest, 125(5 Suppl), 141S (2004) (Pubitemid 38648356)
3. R. S. Herbst, J. V. Heymach and S. M. Lippman: Lung cancer. N Engl J Med, 359(13), 1367-80 (2008)
4. J. R. Molina, A. A. Adjei and J. R. Jett: Advances in chemotherapy of non-small cell lung cancer. Chest, 130(4), 1211-9 (2006) (Pubitemid 44583755)
5. R. Govindan, N. Page, D. Morgensztern, W. Read, R. Tierney, A. Vlahiotis, E. L. Spitznagel and J. Piccirillo: Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol, 24(28), 4539-44 (2006) (Pubitemid 46630948)
6. E. Gonzalez and T. E. McGraw: The Akt kinases: isoform specificity in metabolism and cancer. Cell Cycle, 8(16), 2502-8 (2009)
7. K. M. Nicholson and N. G. Anderson: The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal, 14(5), 381-95 (2002) (Pubitemid 34214843)
8. D. Ruggero and N. Sonenberg: The Akt of translational control. Oncogene, 24(50), 7426-34 (2005) (Pubitemid 41637982)
9. J. D. Richter and N. Sonenberg: Regulation of capdependent translation by eIF4E inhibitory proteins. Nature, 433(7025), 477-80 (2005) (Pubitemid 40204297)
10. V. Serra, B. Markman, M. Scaltriti, P. J. Eichhorn, V. Valero, M. Guzman, M. L. Botero, E. Llonch, F. Atzori, S. Di Cosimo, M. Maira, C. Garcia-Echeverria, J. L. Parra, J. Arribas and J. Baselga: NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res, 68(19), 8022-30 (2008)
11. B. P. Zhou, Y. Liao, W. Xia, B. Spohn, M. H. Lee and M. C. Hung: Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neuoverexpressing cells. Nat Cell Biol, 3(3), 245-52 (2001) (Pubitemid 32201319)
12. P. Blume-Jensen and T. Hunter: Oncogenic kinase signalling. Nature, 411(6835), 355-65 (2001) (Pubitemid 32467045)
13. S. R. Datta, H. Dudek, X. Tao, S. Masters, H. Fu, Y. Gotoh and M. E. Greenberg: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell, 91(2), 231-41 (1997) (Pubitemid 27456390)
14. M. H. Cardone, N. Roy, H. R. Stennicke, G. S. Salvesen, T. F. Franke, E. Stanbridge, S. Frisch and J. C. Reed: Regulation of cell death protease caspase-9 by phosphorylation. Science, 282(5392), 1318-21 (1998) (Pubitemid 28524494)
15. D. A. Altomare and J. R. Testa: Perturbations of the AKT signaling pathway in human cancer. Oncogene, 24(50), 7455-64 (2005) (Pubitemid 41637985)
16. I. Vivanco and C. L. Sawyers: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer, 2(7), 489-501 (2002) (Pubitemid 37328931)
17. S. G. Kennedy, E. S. Kandel, T. K. Cross and N. Hay: Akt/Protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria. Mol Cell Biol, 19(8), 5800-10 (1999) (Pubitemid 29339934)
18. P. Brodt, A. Samani and R. Navab: Inhibition of the type I insulin-like growth factor receptor expression and signaling: novel strategies for antimetastatic therapy. Biochem Pharmacol, 60(8), 1101-7 (2000)
19. K. H. Chun, J. W. Kosmeder, 2nd, S. Sun, J. M. Pezzuto, R. Lotan, W. K. Hong and H. Y. Lee: Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. J Natl Cancer Inst, 95(4), 291-302 (2003) (Pubitemid 36336479)
20. K. A. West, J. Brognard, A. S. Clark, I. R. Linnoila, X. Yang, S. M. Swain, C. Harris, S. Belinsky and P. A. Dennis: Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest, 111(1), 81-90 (2003) (Pubitemid 36134851)
21. B. R. Balsara, J. Pei, Y. Mitsuuchi, R. Page, A. Klein-Szanto, H. Wang, M. Unger and J. R. Testa: Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis, 25(11), 2053-9 (2004) (Pubitemid 39534841)
22. A. S. Tsao, T. McDonnell, S. Lam, J. B. Putnam, N. Bekele, W. K. Hong and J. M. Kurie: Increased phospho-AKT (Ser (473)) expression in bronchial dysplasia: implications for lung cancer prevention studies. Cancer Epidemiol Biomarkers Prev, 12(7), 660-4 (2003) (Pubitemid 36899849)
23. J. W. Tichelaar, Y. Zhang, J. C. leRiche, P. W. Biddinger, S. Lam and M. W. Anderson: Increased staining for phospho-Akt, p65/RELA and cIAP-2 in pre-neoplastic human bronchial biopsies. BMC Cancer, 5, 155 (2005)
24. P. P. Massion, W. L. Kuo, D. Stokoe, A. B. Olshen, P. A. Treseler, K. Chin, C. Chen, D. Polikoff, A. N. Jain, D. Pinkel, D. G. Albertson, D. M. Jablons and J. W. Gray: Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res, 62(13), 3636-40 (2002) (Pubitemid 34728838)
25. J. Brognard, A. S. Clark, Y. Ni and P. A. Dennis: Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res, 61(10), 3986-97 (2001) (Pubitemid 32720961)
26. J. M. Kurie: Role of protein kinase B-dependent signaling in lung tumorigenesis. Chest, 125(5 Suppl), 141S-4S (2004) (Pubitemid 38648357)
27. J. Tsurutani, J. Fukuoka, H. Tsurutani, J. H. Shih, S. M. Hewitt, W. D. Travis, J. Jen and P. A. Dennis: Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. J Clin Oncol, 24(2), 306-14 (2006) (Pubitemid 46622059)
28. F. H. Blackhall, M. Pintilie, M. Michael, N. Leighl, R. Feld, M. S. Tsao and F. A. Shepherd: Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer. Clin Cancer Res, 9(6), 2241-7 (2003) (Pubitemid 36687649)
29. D. Malanga, M. Scrima, C. De Marco, F. Fabiani, N. De Rosa, S. De Gisi, N. Malara, R. Savino, G. Rocco, G. Chiappetta, R. Franco, V. Tirino, G. Pirozzi and G. Viglietto: Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. Cell Cycle, 7(5), 665-9 (2008) (Pubitemid 351499006)
30. J. D. Carpten, A. L. Faber, C. Horn, G. P. Donoho, S. L. Briggs, C. M. Robbins, G. Hostetter, S. Boguslawski, T. Y. Moses, S. Savage, M. Uhlik, A. Lin, J. Du, Y. W. Qian, D. J. Zeckner, G. Tucker-Kellogg, J. Touchman, K. Patel, S. Mousses, M. Bittner, R. Schevitz, M. H. Lai, K. L. Blanchard and J. E. Thomas: A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature, 448(7152), 439-44 (2007) (Pubitemid 47123510)
31. C. X. Xu, D. Jere, H. Jin, S. H. Chang, Y. S. Chung, J. Y. Shin, J. E. Kim, S. J. Park, Y. H. Lee, C. H. Chae, K. H. Lee, G. R. Beck, Jr., C. S. Cho and M. H. Cho: Poly (ester amine)-mediated, aerosol-delivered Akt1 small interfering RNA suppresses lung tumorigenesis. Am J Respir Crit Care Med, 178(1), 60-73 (2008) (Pubitemid 351919194)
32. C. Gridelli, P. Maione and A. Rossi: The potential role of mTOR inhibitors in non-small cell lung cancer. Oncologist, 13(2), 139-47 (2008) (Pubitemid 351342577)
33. R. M. Memmott and P. A. Dennis: The role of the Akt/mTOR pathway in tobacco carcinogen-induced lung tumorigenesis. Clin Cancer Res, 16(1), 4-10 (2010)
34. A. Arcaro, U. K. Khanzada, B. Vanhaesebroeck, T. D. Tetley, M. D. Waterfield and M. J. Seckl: Two distinct phosphoinositide 3-kinases mediate polypeptide growth factor-stimulated PKB activation. EMBO J, 21(19), 5097-108 (2002)
35. K. A. West, I. R. Linnoila, S. A. Belinsky, C. C. Harris and P. A. Dennis: Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3'-kinase/Akt pathway in vitro and in vivo. Cancer Res, 64(2), 446-51 (2004) (Pubitemid 38120880)
36. H. Yamamoto, H. Shigematsu, M. Nomura, W. W. Lockwood, M. Sato, N. Okumura, J. Soh, M. Suzuki, Wistuba, II, K. M. Fong, H. Lee, S. Toyooka, H. Date, W. L. Lam, J. D. Minna and A. F. Gazdar: PIK3CA mutations and copy number gains in human lung cancers. Cancer Res, 68(17), 6913-21 (2008)
37. O. C. Schuurbiers, J. H. Kaanders, H. F. van der Heijden, R. P. Dekhuijzen, W. J. Oyen and J. Bussink: The PI3-K/AKT-pathway and radiation resistance mechanisms in non-small cell lung cancer. J Thorac Oncol, 4(6), 761-7 (2009)
38. R. A. O'Donnell, A. Richter, J. Ward, G. Angco, A. Mehta, K. Rousseau, D. M. Swallow, S. T. Holgate, R. Djukanovic, D. E. Davies and S. J. Wilson: Expression of ErbB receptors and mucins in the airways of long term current smokers. Thorax, 59(12), 1032-40 (2004) (Pubitemid 39573921)
39. F. Lonardo, K. H. Dragnev, S. J. Freemantle, Y. Ma, N. Memoli, D. Sekula, E. A. Knauth, J. S. Beebe and E. Dmitrovsky: Evidence for the epidermal growth factor receptor as a target for lung cancer prevention. Clin Cancer Res, 8(1), 54-60 (2002) (Pubitemid 34101459)
40. M. Marinov, B. Fischer and A. Arcaro: Targeting mTOR signaling in lung cancer. Crit Rev Oncol Hematol, 63(2), 172-82 (2007) (Pubitemid 46990916)
41. T. J. Lynch, D. W. Bell, R. Sordella, S. Gurubhagavatula, R. A. Okimoto, B. W. Brannigan, P. L. Harris, S. M. Haserlat, J. G. Supko, F. G. Haluska, D. N. Louis, D. C. Christiani, J. Settleman and D. A. Haber: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 350(21), 2129-39 (2004) (Pubitemid 38637993)
42. S. Zimmer, P. Kahl, T. M. Buhl, S. Steiner, E. Wardelmann, S. Merkelbach-Bruse, R. Buettner and L. C. Heukamp: Epidermal growth factor receptor mutations in non-small cell lung cancer influence downstream Akt, MAPK and Stat3 signaling. J Cancer Res Clin Oncol, 135(5), 723-30 (2009)
43. S. K. Batra, S. Castelino-Prabhu, C. J. Wikstrand, X. Zhu, P. A. Humphrey, H. S. Friedman and D. D. Bigner: Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ, 6(10), 1251-9 (1995)
44. M. W. Pedersen, M. Meltorn, L. Damstrup and H. S. Poulsen: The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann Oncol, 12(6), 745-60 (2001) (Pubitemid 32655082)
45. K. Inamura, H. Ninomiya, Y. Ishikawa and O. Matsubara: Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features? Arch Pathol Lab Med, 134(1), 66-72 (2010)
46. K. Okudela, H. Hayashi, T. Ito, T. Yazawa, T. Suzuki, Y. Nakane, H. Sato, H. Ishi, X. KeQin, A. Masuda, T. Takahashi and H. Kitamura: K-ras gene mutation enhances motility of immortalized airway cells and lung adenocarcinoma cells via Akt activation: possible contribution to non-invasive expansion of lung adenocarcinoma. Am J Pathol, 164(1), 91-100 (2004) (Pubitemid 38364594)
47. W. H. Westra, R. J. Slebos, G. J. Offerhaus, S. N. Goodman, S. G. Evers, T. W. Kensler, F. B. Askin, S. Rodenhuis and R. H. Hruban: K-ras oncogene activation in lung adenocarcinomas from former smokers. Evidence that K-ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung. Cancer, 72(2), 432-8 (1993) (Pubitemid 23193449)
48. S. A. Matzinger, K. A. Crist, G. D. Stoner, M. W. Anderson, M. A. Pereira, V. E. Steele, G. J. Kelloff, R. A. Lubet and M. You: K-ras mutations in lung tumors from A/J and A/J x TSG-p53 F1 mice treated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and phenethyl isothiocyanate. Carcinogenesis, 16(10), 2487-92 (1995)
49. C. J. Marsit, S. Zheng, K. Aldape, P. W. Hinds, H. H. Nelson, J. K. Wiencke and K. T. Kelsey: PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol, 36(7), 768-76 (2005) (Pubitemid 41112032)
50. J. M. Tang, Q. Y. He, R. X. Guo and X. J. Chang: Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer, 51(2), 181-91 (2006)
51. J. G. Zhang, J. J. Wang, F. Zhao, Q. Liu, K. Jiang and G. H. Yang: MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta (2010)
52. R. J. Mayoral, M. E. Pipkin, M. Pachkov, E. van Nimwegen, A. Rao and S. Monticelli: MicroRNA-221-222 regulate the cell cycle in mast cells. J Immunol, 182(1), 433-45 (2009)
53. J. C. Soria, H. Y. Lee, J. I. Lee, L. Wang, J. P. Issa, B. L. Kemp, D. D. Liu, J. M. Kurie, L. Mao and F. R. Khuri: Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res, 8(5), 1178-84 (2002) (Pubitemid 34517656)
54. R. Noro, A. Gemma, A. Miyanaga, S. Kosaihira, Y. Minegishi, M. Nara, Y. Kokubo, M. Seike, K. Kataoka, K. Matsuda, T. Okano, A. Yoshimura and S. Kudoh: PTEN inactivation in lung cancer cells and the effect of its recovery on treatment with epidermal growth factor receptor tyrosine kinase inhibitors. Int J Oncol, 31(5), 1157-63 (2007)
55. E. Pisick, S. Jagadeesh and R. Salgia: Receptor tyrosine kinases and inhibitors in lung cancer. ScientificWorldJournal, 4, 589-604 (2004)
56. D. A. Guertin and D. M. Sabatini: An expanding role for mTOR in cancer. Trends Mol Med, 11(8), 353-61 (2005) (Pubitemid 41080576)
57. J. J. Gibbons, R. T. Abraham and K. Yu: Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin Oncol, 36 Suppl 3, S3-S17 (2009)
58. Y. Sancak, C. C. Thoreen, T. R. Peterson, R. A. Lindquist, S. A. Kang, E. Spooner, S. A. Carr and D. M. Sabatini: PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell, 25(6), 903-15 (2007) (Pubitemid 46436534)
59. E. Vander Haar, S. I. Lee, S. Bandhakavi, T. J. Griffin and D. H. Kim: Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol, 9(3), 316-23 (2007) (Pubitemid 46344611)
60. K. Inoki, Y. Li, T. Zhu, J. Wu and K. L. Guan: TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol, 4(9), 648-57 (2002) (Pubitemid 34993700)
61. B. D. Manning, A. R. Tee, M. N. Logsdon, J. Blenis and L. C. Cantley: Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell, 10(1), 151-62 (2002) (Pubitemid 34876569)
62. A. Garami, F. J. Zwartkruis, T. Nobukuni, M. Joaquin, M. Roccio, H. Stocker, S. C. Kozma, E. Hafen, J. L. Bos and G. Thomas: Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell, 11(6), 1457-66 (2003) (Pubitemid 36776533)
63. S. Han, F. R. Khuri and J. Roman: Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMPactivated protein kinase signal pathways. Cancer Res, 66(1), 315-23 (2006) (Pubitemid 43166038)
64. J. Tsurutani, S. S. Castillo, J. Brognard, C. A. Granville, C. Zhang, J. J. Gills, J. Sayyah and P. A. Dennis: Tobacco components stimulate Akt-dependent proliferation and NFkappaB-dependent survival in lung cancer cells. Carcinogenesis, 26(7), 1182-95 (2005) (Pubitemid 41417895)
65. J. S. Keum, G. Kong, S. C. Yang, D. H. Shin, S. S. Park, J. H. Lee and J. D. Lee: Cyclin D1 overexpression is an indicator of poor prognosis in resectable non-small cell lung cancer. Br J Cancer, 81(1), 127-32 (1999) (Pubitemid 29415502)
66. M. Ikehara, F. Oshita, H. Ito, N. Ohgane, R. Suzuki, H. Saito, K. Yamada, K. Noda, A. Mitsuda and Y. Kameda: Expression of cyclin D1 but not of cyclin E is an indicator of poor prognosis in small adenocarcinomas of the lung. Oncol Rep, 10(1), 137-9 (2003)
67. J. A. Diehl, F. Zindy and C. J. Sherr: Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev, 11(8), 957-72 (1997) (Pubitemid 27199876)
68. J. A. Diehl, M. Cheng, M. F. Roussel and C. J. Sherr: Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev, 12(22), 3499-511 (1998) (Pubitemid 28553242)
69. J. Liang and J. M. Slingerland: Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle, 2(4), 339-45 (2003)
70. G. Sithanandam, G. T. Smith, A. Masuda, T. Takahashi, L. M. Anderson and L. W. Fornwald: Cell cycle activation in lung adenocarcinoma cells by the ErbB3/phosphatidylinositol 3-kinase/Akt pathway. Carcinogenesis, 24(10), 1581-92 (2003) (Pubitemid 37304663)
71. M. A. Bjornsti and P. J. Houghton: Lost in translation: dysregulation of cap-dependent translation and cancer. Cancer Cell, 5(6), 519-23 (2004) (Pubitemid 38748913)
72. H. Kawana, J. Tamaru, T. Tanaka, A. Hirai, Y. Saito, M. Kitagawa, A. Mikata, K. Harigaya and T. Kuriyama: Role of p27Kip1 and cyclin-dependent kinase 2 in the proliferation of non-small cell lung cancer. Am J Pathol, 153(2), 505-13 (1998) (Pubitemid 28373661)
73. S. Tsukamoto, K. Sugio, T. Sakada, C. Ushijima, K. Yamazaki and K. Sugimachi: Reduced expression of cellcycle regulator p27 (Kip1) correlates with a shortened survival in non-small cell lung cancer. Lung Cancer, 34(1), 83-90 (2001) (Pubitemid 32824127)
74. S. Mohamed, K. Yasufuku, K. Hiroshima, T. Nakajima, S. Yoshida, M. Suzuki, Y. Sekine, K. Shibuya, T. Iizasa, A. Farouk and T. Fujisawa: Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer. Cancer, 109(12), 2506-14 (2007) (Pubitemid 46906470)
75. S. Ishihara, K. Minato, H. Hoshino, R. Saito, F. Hara, T. Nakajima and M. Mori: The cyclin-dependent kinase inhibitor p27 as a prognostic factor in advanced non-small cell lung cancer: its immunohistochemical evaluation using biopsy specimens. Lung Cancer, 26(3), 187-94 (1999) (Pubitemid 30114221)
76. A. Bellacosa, C. C. Kumar, A. Di Cristofano and J. R. Testa: Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res, 94, 29-86 (2005) (Pubitemid 41202364)
77. R. Mamillapalli, N. Gavrilova, V. T. Mihaylova, L. M. Tsvetkov, H. Wu, H. Zhang and H. Sun: PTEN regulates the ubiquitin-dependent degradation of the CDK inhibitor p27 (KIP1) through the ubiquitin E3 ligase SCF (SKP2). Curr Biol, 11(4), 263-7 (2001) (Pubitemid 32185329)
78. L. Hengst and S. I. Reed: Translational control of p27Kip1 accumulation during the cell cycle. Science, 271(5257), 1861-4 (1996)
79. K. S. Kelly-Spratt, J. Philipp-Staheli, K. E. Gurley, K. Hoon-Kim, S. Knoblaugh and C. J. Kemp: Inhibition of PI-3K restores nuclear p27Kip1 expression in a mouse model of Kras-driven lung cancer. Oncogene, 28(41), 3652-62 (2009)
80. Y. Sun and Z. L. Peng: Programmed cell death and cancer. Postgrad Med J, 85(1001), 134-40 (2009)
81. J. A. Call, S. G. Eckhardt and D. R. Camidge: Targeted manipulation of apoptosis in cancer treatment. Lancet Oncol, 9(10), 1002-11 (2008)
82. C. X. Xu, H. Jin and M. H. Cho: Apoptosis and Apoptosis-Based Therapy in Lung Cancer. Anticancer Agents Med Chem (2009)
83. H. Schulze-Bergkamen and P. H. Krammer: Apoptosis in cancer-implications for therapy. Semin Oncol, 31(1), 90-119 (2004)
84. D. C. Altieri: Validating survivin as a cancer therapeutic target. Nat Rev Cancer, 3(1), 46-54 (2003) (Pubitemid 37328886)
85. U. Zangemeister-Wittke and H. U. Simon: An IAP in action: the multiple roles of survivin in differentiation, immunity and malignancy. Cell Cycle, 3(9), 1121-3 (2004) (Pubitemid 40268627)
86. M. Monzo, R. Rosell, E. Felip, J. Astudillo, J. J. Sanchez, J. Maestre, C. Martin, A. Font, A. Barnadas and A. Abad: A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in nonsmallcell lung cancers. J Clin Oncol, 17(7), 2100-4 (1999) (Pubitemid 29318841)
87. L. L. Belyanskaya, S. Hopkins-Donaldson, S. Kurtz, A. P. Simoes-Wust, S. Yousefi, H. U. Simon, R. Stahel and U. Zangemeister-Wittke: Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation. Int J Cancer, 117(5), 755-63 (2005) (Pubitemid 41598826)
88. M. Xin and X. Deng: Nicotine inactivation of the proapoptotic function of Bax through phosphorylation. J Biol Chem, 280(11), 10781-9 (2005) (Pubitemid 40395941)
89. S. Rokudai, N. Fujita, O. Kitahara, Y. Nakamura and T. Tsuruo: Involvement of FKHR-dependent TRADD expression in chemotherapeutic drug-induced apoptosis. Mol Cell Biol, 22(24), 8695-708 (2002) (Pubitemid 35397183)
90. P. F. Dijkers, R. H. Medema, J. W. Lammers, L. Koenderman and P. J. Coffer: Expression of the proapoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol, 10(19), 1201-4 (2000)
91. E. L. Greer and A. Brunet: FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene, 24(50), 7410-25 (2005) (Pubitemid 41637981)
92. H. Matsuzaki, H. Daitoku, M. Hatta, K. Tanaka and A. Fukamizu: Insulin-induced phosphorylation of FKHR (Foxo1) targets to proteasomal degradation. Proc Natl Acad Sci U S A, 100(20), 11285-90 (2003) (Pubitemid 37205927)
93. D. R. Plas and C. B. Thompson: Akt activation promotes degradation of tuberin and FOXO3a via the proteasome. J Biol Chem, 278(14), 12361-6 (2003) (Pubitemid 36800220)
94. H. Huang, K. M. Regan, F. Wang, D. Wang, D. I. Smith, J. M. van Deursen and D. J. Tindall: Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc Natl Acad Sci U S A, 102(5), 1649-54 (2005) (Pubitemid 40209222)
95. D. Gao, H. Inuzuka, A. Tseng and W. Wei: Akt finds its new path to regulate cell cycle through modulating Skp2 activity and its destruction by APC/Cdh1. Cell Div, 4, 11 (2009)
96. T. Maekawa, Y. Maniwa, T. Doi, W. Nishio, M. Yoshimura, C. Ohbayashi, Y. Hayashi and Y. Okita: Expression and localization of FOXO1 in non-small cell lung cancer. Oncol Rep, 22(1), 57-64 (2009)
97. B. H. Jiang and L. Z. Liu: PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res, 102, 19-65 (2009)
98. D. T. Merrick, J. Haney, S. Petrunich, M. Sugita, Y. E. Miller, R. L. Keith, T. C. Kennedy and W. A. Franklin: Overexpression of vascular endothelial growth factor and its receptors in bronchial dypslasia demonstrated by quantitative RT-PCR analysis. Lung Cancer, 48(1), 31-45 (2005) (Pubitemid 40380998)
99. D. Stefanou, A. Batistatou, E. Arkoumani, E. Ntzani and N. J. Agnantis: Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in small-cell and non-small-cell lung carcinomas. Histol Histopathol, 19(1), 37-42 (2004) (Pubitemid 38111247)
100. P. Salven, T. Ruotsalainen, K. Mattson and H. Joensuu: High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer, 79(2), 144-6 (1998) (Pubitemid 28201685)
101. G. Fontanini, P. Faviana, M. Lucchi, L. Boldrini, A. Mussi, T. Camacci, M. A. Mariani, C. A. Angeletti, F. Basolo and R. Pingitore: A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br J Cancer, 86(4), 558-63 (2002) (Pubitemid 34185092)
102. N. Pore, A. K. Gupta, G. J. Cerniglia, Z. Jiang, E. J. Bernhard, S. M. Evans, C. J. Koch, S. M. Hahn and A. Maity: Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapy. Cancer Res, 66(18), 9252-9 (2006) (Pubitemid 44521147)
103. G. L. Semenza: Targeting HIF-1 for cancer therapy. Nat Rev Cancer, 3(10), 721-32 (2003) (Pubitemid 37328811)
104. C. C. Hudson, M. Liu, G. G. Chiang, D. M. Otterness, D. C. Loomis, F. Kaper, A. J. Giaccia and R. T. Abraham: Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol, 22(20), 7004-14 (2002)
105. C. Chetty, S. S. Lakka, P. Bhoopathi and J. S. Rao: MMP-2 alters VEGF expression via alphaVbeta3 integrinmediated PI3K/AKT signaling in A549 lung cancer cells. Int J Cancer (2009)
106. G. L. Semenza: HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol, 88(4), 1474-80 (2000) (Pubitemid 30217451)
107. J. Fang, Q. Zhou, L. Z. Liu, C. Xia, X. Hu, X. Shi and B. H. Jiang: Apigenin inhibits tumor angiogenesis through decreasing HIF-1alpha and VEGF expression. Carcinogenesis, 28(4), 858-64 (2007) (Pubitemid 46523341)
108. L. Z. Liu, J. Fang, Q. Zhou, X. Hu, X. Shi and B. H. Jiang: Apigenin inhibits expression of vascular endothelial growth factor and angiogenesis in human lung cancer cells: implication of chemoprevention of lung cancer. Mol Pharmacol, 68(3), 635-43 (2005) (Pubitemid 41206017)
109. L. C. van Kempen and L. M. Coussens: MMP9 potentiates pulmonary metastasis formation. Cancer Cell, 2(4), 251-2 (2002) (Pubitemid 41043957)
110. X. Li and J. F. Wu: Recent Developments in Patent Anti-Cancer Agents Targeting the Matrix Metalloproteinases (MMPs). Recent Pat Anticancer Drug Discov, 5(2), 109-41 (2009)
111. S. Garbisa, G. Scagliotti, L. Masiero, C. Di Francesco, C. Caenazzo, M. Onisto, M. Micela, W. G. Stetler-Stevenson and L. A. Liotta: Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res, 52(16), 4548-9 (1992)
112. E. Hrabec, M. Strek, D. Nowak and Z. Hrabec: Elevated level of circulating matrix metalloproteinase-9 in patients with lung cancer. Respir Med, 95(1), 1-4 (2001) (Pubitemid 32621978)
113. H. Sasaki, H. Yukiue, S. Moiriyama, Y. Kobayashi, Y. Nakashima, M. Kaji, M. Kiriyama, I. Fukai, Y. Yamakawa and Y. Fujii: Clinical significance of matrix metalloproteinase-7 and Ets-1 gene expression in patients with lung cancer. J Surg Res, 101(2), 242-7 (2001) (Pubitemid 34044566)
114. A. A. Thant, A. Nawa, F. Kikkawa, Y. Ichigotani, Y. Zhang, T. T. Sein, A. R. Amin and M. Hamaguchi: Fibronectin activates matrix metalloproteinase-9 secretion via the MEK1-MAPK and the PI3K-Akt pathways in ovarian cancer cells. Clin Exp Metastasis, 18(5), 423-8 (2000) (Pubitemid 32588623)
115. S. Han, J. D. Ritzenthaler, S. V. Sitaraman and J. Roman: Fibronectin increases matrix metalloproteinase 9 expression through activation of c-Fos via extracellular-regulated kinase and phosphatidylinositol 3-kinase pathways in human lung carcinoma cells. J Biol Chem, 281(40), 29614-24 (2006) (Pubitemid 44536969)
116. Y. C. Lee, H. H. Lin, C. H. Hsu, C. J. Wang, T. A. Chiang and J. H. Chen: Inhibitory effects of andrographolide on migration and invasion in human non-small cell lung cancer A549 cells via down-regulation of PI3K/Akt signaling pathway. Eur J Pharmacol, 632(1-3), 23-32 (2010)
117. K. Jiang, J. Sun, J. Cheng, J. Y. Djeu, S. Wei and S. Sebti: Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis. Mol Cell Biol, 24(12), 5565-76 (2004) (Pubitemid 38738186)
118. Y. W. Shih, P. S. Chen, C. H. Wu, Y. F. Jeng and C. J. Wang: Alpha-chaconine-reduced metastasis involves a PI3K/Akt signaling pathway with downregulation of NFkappaB in human lung adenocarcinoma A549 cells. J Agric Food Chem, 55(26), 11035-43 (2007)
119. P. Dent, A. Yacoub, J. Contessa, R. Caron, G. Amorino, K. Valerie, M. P. Hagan, S. Grant and R. Schmidt-Ullrich: Stress and radiation-induced activation of multiple intracellular signaling pathways. Radiat Res, 159(3), 283-300 (2003) (Pubitemid 36314943)
120. J. Y. Hung, Y. L. Hsu, C. T. Li, Y. C. Ko, W. C. Ni, M. S. Huang and P. L. Kuo: 6-Shogaol, an Active Constituent of Dietary Ginger, Induces Autophagy by Inhibiting the AKT/mTOR Pathway in Human Non-Small Cell Lung Cancer A549 Cells. J Agric Food Chem (2009)
121. F. H. Igney and P. H. Krammer: Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer, 2(4), 277-88 (2002) (Pubitemid 37328781)
122. X. Wang, W. Chen, W. Zeng, L. Bai, Y. Tesfaigzi, S. A. Belinsky and Y. Lin: Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAILinduced cytotoxicity to lung cancer cells. Mol Cancer Ther, 7(5), 1156-63 (2008)
123. A. C. Kraus, I. Ferber, S. O. Bachmann, H. Specht, A. Wimmel, M. W. Gross, J. Schlegel, G. Suske and M. Schuermann: In vitro chemo-and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways. Oncogene, 21(57), 8683-95 (2002) (Pubitemid 36132389)
124. D. Guo, I. J. Hildebrandt, R. M. Prins, H. Soto, M. M. Mazzotta, J. Dang, J. Czernin, J. Y. Shyy, A. D. Watson, M. Phelps, C. G. Radu, T. F. Cloughesy and P. S. Mischel: The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc Natl Acad Sci U S A, 106(31), 12932-7 (2009)
125. R. K. Amaravadi, D. Yu, J. J. Lum, T. Bui, M. A. Christophorou, G. I. Evan, A. Thomas-Tikhonenko and C. B. Thompson: Autophagy inhibition enhances therapyinduced apoptosis in a Myc-induced model of lymphoma. J Clin Invest, 117(2), 326-36 (2007) (Pubitemid 46203961)
126. S. Pattingre, L. Espert, M. Biard-Piechaczyk and P. Codogno: Regulation of macroautophagy by mTOR and Beclin 1 complexes. Biochimie, 90(2), 313-23 (2008) (Pubitemid 351181247)
127. K. M. Livesey, D. Tang, H. J. Zeh and M. T. Lotze: Autophagy inhibition in combination cancer treatment. Curr Opin Investig Drugs, 10(12), 1269-79 (2009)
128. M. C. Maiuri, E. Zalckvar, A. Kimchi and G. Kroemer: Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol, 8(9), 741-52 (2007) (Pubitemid 47312826)
129. L. Fu, Y. A. Kim, X. Wang, X. Wu, P. Yue, S. Lonial, F. R. Khuri and S. Y. Sun: Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. Cancer Res, 69(23), 8967-76 (2009)
130. P. Hilgard, T. Klenner, J. Stekar, G. Nossner, B. Kutscher and J. Engel: D-21266, a new heterocyclic alkylphospholipid with antitumour activity. Eur J Cancer, 33(3), 442-6 (1997) (Pubitemid 27168072)
131. H. A. Elrod, Y. D. Lin, P. Yue, X. Wang, S. Lonial, F. R. Khuri and S. Y. Sun: The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway. Mol Cancer Ther, 6(7), 2029-38 (2007) (Pubitemid 47052493)
132. H. Y. Lee, S. H. Oh, J. K. Woo, W. Y. Kim, C. S. Van Pelt, R. E. Price, D. Cody, H. Tran, J. M. Pezzuto, R. M. Moriarty and W. K. Hong: Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesis. J Natl Cancer Inst, 97(22), 1695-9 (2005) (Pubitemid 41672236)
133. H. Y. Lee, Y. A. Suh, J. W. Kosmeder, J. M. Pezzuto, W. K. Hong and J. M. Kurie: Deguelin-induced inhibition of cyclooxygenase-2 expression in human bronchial epithelial cells. Clin Cancer Res, 10(3), 1074-9 (2004) (Pubitemid 38198909)
134. H. Jin, C. X. Xu, H. W. Kim, Y. S. Chung, J. Y. Shin, S. H. Chang, S. J. Park, E. S. Lee, S. K. Hwang, J. T. Kwon, A. Minai-Tehrani, M. Woo, M. S. Noh, H. J. Youn, D. Y. Kim, B. I. Yoon, K. H. Lee, T. H. Kim, C. S. Cho and M. H. Cho: Urocanic acid-modified chitosan-mediated PTEN delivery via aerosol suppressed lung tumorigenesis in K-ras (LA1) mice. Cancer Gene Ther, 15(5), 275-83 (2008) (Pubitemid 351508133)
135. K. Yu, J. Lucas, T. Zhu, A. Zask, C. Gaydos, L. Toral-Barza, J. Gu, F. Li, I. Chaudhary, P. Cai, J. Lotvin, R. Petersen, M. Ruppen, M. Fawzi, S. Ayral-Kaloustian, J. Skotnicki, T. Mansour, P. Frost and J. Gibbons: PWT-458, a novel pegylated-17-hydroxywortmannin, inhibits phosphatidylinositol 3-kinase signaling and suppresses growth of solid tumors. Cancer Biol Ther, 4(5), 538-45 (2005) (Pubitemid 41351227)
136. R. I. Feldman, J. M. Wu, M. A. Polokoff, M. J. Kochanny, H. Dinter, D. Zhu, S. L. Biroc, B. Alicke, J. Bryant, S. Yuan, B. O. Buckman, D. Lentz, M. Ferrer, M. Whitlow, M. Adler, S. Finster, Z. Chang and D. O. Arnaiz: Novel small molecule inhibitors of 3-phosphoinositidedependent kinase-1. J Biol Chem, 280(20), 19867-74 (2005) (Pubitemid 41379514)
137. D. J. Boffa, F. Luan, D. Thomas, H. Yang, V. K. Sharma, M. Lagman and M. Suthanthiran: Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer. Clin Cancer Res, 10(1 Pt 1), 293-300 (2004) (Pubitemid 38114192)
138. G. Konstantinidou, E. A. Bey, A. Rabellino, K. Schuster, M. S. Maira, A. F. Gazdar, A. Amici, D. A. Boothman and P. P. Scaglioni: Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of nonsmall cell lung cancer harboring K-RAS mutations. Cancer Res, 69(19), 7644-52 (2009)
139. J. Qian, Y. Zou, J. S. Rahman, B. Lu and P. P. Massion: Synergy between phosphatidylinositol 3-kinase/Akt pathway and Bcl-xL in the control of apoptosis in adenocarcinoma cells of the lung. Mol Cancer Ther, 8(1), 101-9 (2009)
140. M. L. Sos, M. Koker, B. A. Weir, S. Heynck, R. Rabinovsky, T. Zander, J. M. Seeger, J. Weiss, F. Fischer, P. Frommolt, K. Michel, M. Peifer, C. Mermel, L. Girard, M. Peyton, A. F. Gazdar, J. D. Minna, L. A. Garraway, H. Kashkar, W. Pao, M. Meyerson and R. K. Thomas: PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res, 69(8), 3256-61 (2009)
141. N. T. Ihle, G. Paine-Murrieta, M. I. Berggren, A. Baker, W. R. Tate, P. Wipf, R. T. Abraham, D. L. Kirkpatrick and G. Powis: The phosphatidylinositol-3- kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Mol Cancer Ther, 4(9), 1349-57 (2005)